Supplementation of PQQ from pregnancy prevents MK-801-induced schizophrenia-like behaviors in mice

被引:0
作者
Ying Peng
Dong Xu
Yuedi Ding
Xingqin Zhou
机构
[1] Jiangsu Institute of Nuclear Medicine,NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine
[2] School of Pharmacy,Department of Radiopharmaceuticals
[3] Nanjing Medical University,undefined
来源
Psychopharmacology | 2022年 / 239卷
关键词
NMDA receptor; MK-801; Pyrroloquinoline quinone; Schizophrenia; Prevention;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2263 / 2275
页数:12
相关论文
共 308 条
[1]  
Adell A(2020)Brain NMDA receptors in schizophrenia and depression Biomolecules 10 947-2369
[2]  
Aizenman E(1992)Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-D-aspartate receptor redox modulatory site J Neurosci 12 2362-192
[3]  
Hartnett KA(1994)Further evidence that pyrroloquinoline quinone interacts with the receptor redox site in rat cortical neurons in vitro Neurosci Lett 168 189-10530
[4]  
Zhong C(2020)Nuclear respiratory factor 1 (NRF-1) upregulates the expression and function of reduced folate carrier (RFC) at the blood-brain barrier FASEB J 34 10516-293
[5]  
Gallop PM(1998)Pyrroloquinoline quinone: a novel vitamin? Nutr Rev 56 287-256
[6]  
Rosenberg PA(2001)A plausible model of schizophrenia must incorporate psychological and social as well as neuro developmental risk factors Dialogues Clin Neurosci 3 243-404
[7]  
Aizenman E(2005)Dermatoglyphics and Schizophrenia: a meta-analysis and investigation of the impact of obstetric complications upon a-b ridge count Schizophr Res 75 399-62
[8]  
Jensen FE(2018)NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update Neuropharmacology 142 41-771
[9]  
Gallop PM(2016)The economic burden of schizophrenia in the United States in 2013 J Clin Psychiatry 77 764-534
[10]  
Rosenberg PA(2020)Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment Neuropsychiatr Dis Treat 16 519-84